As cell and gene therapy has matured, the knowledge base around its uncertainties, risks, and challenges has grown substantially alongside it. Each new therapy that advances through development adds to a growing body of documented obstacles, giving the next generation of CGT programs a roadmap of known issues to incorporate into their own risk mitigation planning rather than rediscovering them independently.
How Do Regulators Approach CGT Risk?
Government agencies have increasingly moved toward providing structured guidance on known CGT risk factors rather than leaving developers to navigate these questions without a framework. The European Medicines Agency, for instance, recommends a risk-based approach that prioritizes the quality, safety, and function of a therapy’s source material above all else. This source-material focus reflects a recurring theme across CGT risk more broadly: many of the field’s most serious risk factors — transmissible spongiform encephalopathy agents, viral contamination, cross-contamination, replication-competent viruses, microbiological contamination, and sterility integrity — trace back to the production chain itself, from initial sourcing through storage, transport, environmental control, and equipment dedication.
How Does MKA Insights Categorize CGT Risk?
At MKA Insights, we find it useful to sort CGT risk into three distinct categories: challenges, risks, and uncertainties. Challenges are research-specific hurdles that must be overcome to better understand a disease or a therapy’s mechanism of action. Risks are known issues that pose a direct safety concern when a therapy is administered to patients. Uncertainties are areas where insufficient data currently exists to fully characterize a potential future risk. Each category demands a different kind of mitigation strategy, which is why collapsing them into a single undifferentiated “CGT risk” conversation tends to produce less useful planning than treating them separately.
What Are the Leading Research Challenges in CGT?
Several research challenges recur across CGT programs regardless of specific therapeutic target. Tumor heterogeneity — the broad genetic variability within a single tumor — makes it difficult to identify one antigen or cell clone that’s uniformly effective across the entire targeted population, often requiring researchers to combine approaches, such as pairing a cellular therapy with radiation, to improve overall efficacy. Complex tumor microenvironments compound this difficulty for solid tumor applications specifically: the dense, only partially understood matrix of healthy and diseased tissue surrounding a solid tumor behaves differently from the more accessible environment blood cancers present. The limited utility of animal models adds a third layer of difficulty — because CGT therapies are designed around human biology, testing in rodent or non-human primate models, even humanized ones, leaves real uncertainty about toxicological risk, particularly around the cascading effects of immune responses these therapies can trigger.
What Are the Most Significant Direct Safety Risks?
Several specific, well-documented safety risks recur across CGT modalities. Immunogenicity and immunotoxicity sit at the center of this list — immunogenicity describes a therapy’s potential to provoke an immune response, while immunotoxicity describes the adverse effects that result when that response occurs. Industry experts in biologics development have noted that immunogenicity-related issues are responsible for a substantial share of drug development failures generally, and CGT is no exception; regulators require a formal Immunogenicity Risk Assessment as part of every Investigational New Drug filing, with the required supporting data shaped by the specific drug, its mechanism of action, route and frequency of administration, and the target patient population.
Several related immune risks round out this category. Graft-versus-host disease occurs when transplanted tissue turns against the host’s body — the inverse of the more commonly discussed host-versus-graft rejection. Cytokine release syndrome describes an immune response more aggressive than anticipated, with the potential to cause organ or systemic failure. Therapies incorporating murine-derived antigens or antibodies carry a documented risk of triggering an anti-mouse immune response, a pattern observed early in CAR-T development that limited how many doses certain patients could safely receive. Off-target, on-target, and non-specific binding represent a further category of risk specific to therapies using immune modulators — since cells and therapeutic agents travel within the body after administration, even a therapy delivered to a specific tissue carries some risk of affecting healthy tissue elsewhere. Viral shedding, relevant to therapies using bacterial or viral vectors, refers to vector material leaving the patient’s body after administration, creating both a risk to close contacts and an environmental consideration regulators evaluate as part of the overall risk profile.
How Are These Risks Actually Monitored and Measured?
Naming a risk is only the first step — CGT manufacturers also need specific, validated assay technologies capable of detecting and quantifying each risk in practice. Viral shedding, the release of virus or vector material from a patient via mucosa, urine, semen, or other excreta, is monitored through dedicated shedding studies using PCR or quantitative PCR, distinguishing free viral particles in patient excreta from the broader biodistribution question of where vector material has integrated within the body. Biodistribution studies serve that complementary purpose: tracking the persistence of virus or vector within the body, its on-target and off-target impact, and any indication of potential organ toxicity.
For viral vector products specifically, the ratio of full-to-empty viral capsids has become a recognized CQA in its own right. During vector manufacturing, the goal is producing capsids fully loaded with the intended genetic payload, but the process inevitably also generates partially filled and empty capsids — material that doesn’t just fail to contribute therapeutic benefit, but actively competes with properly filled capsids for binding sites on target cells, reducing overall transduction efficiency. Measuring and controlling this full-to-empty ratio has become standard practice precisely because it directly affects both potency and the amount of inert material a patient is exposed to.
Cytokine release syndrome — discussed above as a major safety risk — has a specific underlying mechanism worth understanding: a foreign antigen such as a viral particle or vector typically triggers cytokine release as a normal part of immune response, but a severe reaction can escalate into a massive, dysregulated cytokine release often described as a “cytokine storm,” with the potential to cause organ or systemic failure. Monitoring for this risk relies on immunoassay technologies including flow cytometry, ELISA, and PCR-based methods, tracking biomarkers such as inflammatory cytokine levels well before a reaction would otherwise become clinically apparent.
What Remains Genuinely Uncertain?
Two categories of uncertainty remain prominent across CGT development. Prolonged post-administration activity is still being actively characterized: because these therapies are designed to influence gene expression over extended periods, and because the field is still relatively young, there simply hasn’t been enough elapsed time to fully document long-term effects for many therapies — researchers and regulators continue gathering this evidence as treated patient populations age further past treatment. Gene expression interference represents a second, more structurally rooted uncertainty: because many gene therapies integrate into a recipient’s DNA to achieve durable expression, there’s a theoretical risk that this integration could activate or inactivate neighboring genes in ways that aren’t yet fully predictable, with tumor formation as the most serious potential downstream consequence.
What Does This Risk Landscape Mean for the Field Going Forward?
The expanding body of documented knowledge around CGT challenges, risks, and uncertainties is, on balance, a genuinely positive development for the field rather than a discouraging one. Each new data point — each documented immunogenicity finding, each characterized off-target effect, each additional year of long-term follow-up data — narrows the uncertainty the next generation of CGT programs has to navigate, and contributes directly to the field’s ability to develop and approve new therapies in shorter timeframes than were possible even a few years earlier.